Robert B. MacArthur
PharmD, MS CEO
Robert B. MacArthur earned his PharmD at St. John's University, in New York, and MS in Biostatistics at Columbia University, also in New York.
For over 30 years he has been continuously engaged in the fields of commercial drug development, clinical research, and research pharmacy. His experience includes large pharma (Sandoz, Novartis), small/mid pharma (Systems Medicines, CTI, Aeson Therapeutics, Cancer Prevention Pharmaceuticals, multiple others), and academia, along with running his
Bruce Levin, Ph.D.
Bruce Levin, Ph.D., is Professor and Past Chair of the Department of Biostatistics at Columbia University’s Mailman School of Public Health. He has a long-standing interest in statistical methodology for clinical trials, public health, and the law. Using sequential statistical methods, he has published on innovative trial designs, e.g., designs that minimize ethical costs, designs that emphasize the selection paradigm rather than the significance testing paradigm, and novel designs such as the comparative selection trial which combines features of both paradigms. For example, in May of 2009 he gave a short course to the FDA/CDER biostatistics group entitled, “Selection Methods in Clinical Trials.”
Arman Altincatal, Ph.D.
Senior Programmer and Statistician
Arman Altincatal, MS, is a pharmaceutical industry based senior statistician. Mr. Altincatal specializes in statistical methods for clinical trials and observational (large epidemiological cohort) data analyses. He is familiar with a broad range of statistical methods, such as mixed models, repeated measures logistic regression, and survival analysis with time-dependent predictors.
Seamus (John L P) Thompson, Ph.D.
Director of the Statistical Analysis Center (SAC)
Seamus (John L P) Thompson PhD is a Professor of Clinical Biostatistics and Clinical Neurology at Columbia University and Director of the Statistical Analysis Center (SAC) in the Department of Biostatistics. He is an applied statistician specializing in innovative collaborations in prevalent and rare neurological and other disorders. He has, with colleagues, developed an approach to clinical trials and which combines collaboration with eminent clinical investigators, innovative statistical designs, and advanced, customized, flexible, user-friendly data management systems. Seamus has served as Principal Investigator for Statistics and Data Management in major NIH multicenter trials (WARCEF, TNK, QALS, and has participated in industry trials (GAIN, Abciximab, ReoPro) and other collaborations, such as the NIH-funded North American Mitochondrial Research Consortium (NAMDC). He has also served on many trial Data and Safety Monitoring Boards (DSMBs).